Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-?, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples